CLVS.Q Stock Overview
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Clovis Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.015 |
| 52 Week High | US$2.87 |
| 52 Week Low | US$0.01 |
| Beta | 0.66 |
| 1 Month Change | -40.00% |
| 3 Month Change | -28.57% |
| 1 Year Change | -99.39% |
| 3 Year Change | -99.77% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.88% |
Recent News & Updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Shareholder Returns
| CLVS.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.1% | 2.8% | 3.0% |
| 1Y | -99.4% | -6.8% | 10.1% |
Return vs Industry: CLVS.Q underperformed the US Biotechs industry which returned 2.5% over the past year.
Return vs Market: CLVS.Q underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CLVS.Q's share price has been volatile over the past 3 months.
Volatility Over Time: CLVS.Q's weekly volatility has increased from 39% to 61% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Clovis Oncology, Inc. Fundamentals Summary
| CLVS.Q fundamental statistics | |
|---|---|
| Market cap | US$2.18m |
| Earnings (TTM) | -US$251.91m |
| Revenue (TTM) | US$133.02m |
0.0x
P/S Ratio0.0x
P/E RatioIs CLVS.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLVS.Q income statement (TTM) | |
|---|---|
| Revenue | US$133.02m |
| Cost of Revenue | US$31.59m |
| Gross Profit | US$101.43m |
| Other Expenses | US$353.33m |
| Earnings | -US$251.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 76.25% |
| Net Profit Margin | -189.37% |
| Debt/Equity Ratio | -158.0% |
How did CLVS.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/12 01:06 |
| End of Day Share Price | 2023/07/10 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clovis Oncology, Inc. is covered by 18 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Alethia Young | Credit Suisse |
| Steven Breazzano | Evercore ISI |